Overview

• ADRIANA, Japan’s first non-opioid analgesic, works by selectively blocking α2B-adrenoceptors to elevate noradrenaline and activate pain-suppressing α2A-adrenoceptors without causing cardiovascular instability.
• Phase I clinical trials in healthy volunteers at Kyoto University Hospital confirmed ADRIANA’s favorable safety and tolerability profile.
• Phase II studies in postoperative lung cancer surgery patients at Kyoto University Hospital demonstrated significant pain relief with ADRIANA.
• Results of the early-phase trials and mechanistic data were published on August 4, 2025, in the Proceedings of the National Academy of Sciences.
• BTB Therapeutics, Inc. is partnering with Kyoto University to prepare a multicenter U.S. Phase II trial aimed at evaluating ADRIANA as an alternative to opioid painkillers.